Disc Medicine is laying off a fifth of its workforce as the biotech reels from the FDA’s rejection of its rare blood disease candidate. | Disc Medicine is laying off a fifth of its workforce as the ...
Synergy Spine Solutions has received premarket approval (PMA) from the US Food and Drug Administration (FDA) for the Synergy ...
This clinical-stage biopharmaceutical company recently had one of its treatments rejected for FDA approval. Now the company ...
Disc Medicine is laying off about 20% of its workforce after the Food and Drug Administration denied its application for accelerated approval of its bitopertin treatment.
By Siddhi Mahatole Feb 17 (Reuters) - Disc Medicine said on Tuesday it will pursue a traditional U.S. approval pathway for ...
Disc Medicine’s leadership tried to express optimism that its rare disease therapy bitopertin can be approved based on a Phase 3 trial set to begin shortly. However, analysts are worried that the ...
The FDA in October 2025 granted bitopertin its Commissioner’s National Priority Voucher but after a shortened review time has decided the data did not support regulatory approval for treating ...
Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.
The PlayStation 5 is finally easy to find after years of scarcity, but before you hit that “add to cart” button, you’ll still have to make an important decision: PS5 Disc or PS5 Digital Edition? And ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results